Balance Sheet
Cash Flow Statement
Amortizatization of IntangiblesCapital ExpendituresCash from Financing ActivitiesCash from Investing ActivitiesCash from OperationsChange in Account PayablesChange in Accured ExpensesChange in CashChange in ReceivablesDepreciation & Amortization (CF)Depreciation and DepletionExchange Rate EffectFree Cash FlowGains from Investment SecuritiesNet Cash FlowNet IncomeOther Working Capital ChangesOther financing activitiesShare-based Compensation
Daily Values
Growth Metrics
Income Statement
Others
Ratios

Cartesian Therapeutics (RNAC) Gains from Investment Securities: 2014-2024

Historic Gains from Investment Securities for Cartesian Therapeutics (RNAC) over the last 11 years, with Dec 2024 value amounting to -$2.6 million.

  • Cartesian Therapeutics' Gains from Investment Securities rose 90.90% to -$516,000 in Q3 2025 from the same period last year, while for Sep 2025 it was -$2.7 million, marking a year-over-year increase of 71.13%. This contributed to the annual value of -$2.6 million for FY2024, which is 79.93% up from last year.
  • Latest data reveals that Cartesian Therapeutics reported Gains from Investment Securities of -$2.6 million as of FY2024, which was up 79.93% from -$12.7 million recorded in FY2023.
  • Over the past 5 years, Cartesian Therapeutics' Gains from Investment Securities peaked at $10.4 million during FY2020, and registered a low of -$20.9 million during FY2022.
  • Moreover, its 3-year median value for Gains from Investment Securities was -$12.7 million (2023), whereas its average is -$12.1 million.
  • Per our database at Business Quant, Cartesian Therapeutics' Gains from Investment Securities spiked by 1,118.55% in 2020 and then tumbled by 992.77% in 2022.
  • Yearly analysis of 5 years shows Cartesian Therapeutics' Gains from Investment Securities stood at $10.4 million in 2020, then crashed by 77.60% to $2.3 million in 2021, then tumbled by 992.77% to -$20.9 million in 2022, then soared by 38.96% to -$12.7 million in 2023, then soared by 79.93% to -$2.6 million in 2024.